Zynex Medical competitors

Kevin Sayer is the Executive Chairman of the board of directors, President and Chief Executive Officer of Dexcom. He joined Dexcom as President and Chief Operating Officer in 2011. In this executive role, Kevin was responsible for research and development, manufacturing, clinical, regulatory, finance, sales and marketing functions. During his tenure with Dexcom, he has been instrumental in leading the development of new technology, including the Dexcom G5 Mobile CGM System, the Dexcom G4 PLATINUM System with Share and several other product launches in the US and Europe. Prior to joining Dexcom, Kevin served as Chief Financial Officer of Biosensors International, a medical technology company focused on the development, manufacturing and commercialization of medical devices used in interventional cardiology and critical care procedures. Kevin also served as CFO of MiniMed, Inc. from 1994 until its acquisition by Medtronic, Inc. in 2001. Kevin received his master's and bachelor’s degrees in Accounting and Information Systems from Brigham Young University.

Vivek Jain is a President at CAREFUSION CORP, Board Member at Envista Holdings Corporation, and Chairman/CEO at ICU MEDICAL INC/DE. He has worked as Pres:Medical Tech & Services at CAREFUSION CORP, Pres:Procedural Solutions at CAREFUSION CORP, and Mng Dir/Investment Banker at JPMorgan Chase & Co. Vivek studied at University of Chicago.

Erik Gershwind is MSC Industrial Supply Co.'s President and Chief Executive Officer. He served as President and Chief Operating Officer from 2011-2012, was named Executive Vice President and Chief Operating Officer in 2009 and was elected to MSC's Board of Directors in October 2010. For more than 15 years, Erik has managed key aspects of MSC's business, beginning with mergers and acquisitions in 1996 and expanding into sales, product management, marketing and e-Commerce. Since 2008, Erik has led the company's strategic team responsible for directing the business into new growth markets. In 1999, Erik established MSC's highly successful internet business that today features more than 900,000 products and represents more than 41 percent of the company's revenue.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Ed was named president & chief executive officer of Owens & Minor, effective March 7, 2019, and was appointed to the board of directors at the same time. Prior to that, Ed served as an independent consultant and advisor in the healthcare, life science and distribution industries since January 2016. From January 2000 through April 2015, he served in various roles of increasing responsibility at Thermo Fisher Scientific, a $17 billion manufacturer and supplier of a range of products to the research, healthcare, industrial and safety markets, including most recently as chief commercial officer & senior vice president. Before joining Thermo Fisher Scientific, Ed spent eight years at TRW Inc., in a variety of finance roles and three years with PricewaterhouseCoopers as an auditor.

Michael “Mick” Farrell was appointed ResMed’s CEO and has served as a director since March 2013. He joined the company in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and various senior roles in marketing and business development. Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, DowDuPont, and BHP Billiton. Mick serves on the board of directors of ResMed, the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a multibillion dollar public company that provides implantable musculoskeletal medical devices for patients globally. He is also a member of two committees at Zimmer Biomet: Nominating and Governance as well as Compensation and Management Development. He also volunteers as a trustee for non-profit organizations: UC San Diego Foundation, Rady Children’s Hospital, the La Jolla Playhouse, and Father Joe’s Villages in San Diego, California. Mick holds a bachelor of engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology, and a Master of Business Administration from the MIT Sloan School of Management.

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

John F. Sheridan has served as our President and Chief Executive Officer since March 2019 and as a member of our Board of Directors since June 2019. Prior to joining our company, Mr. Sheridan served as Chief Operating Officer of Rapiscan Systems, Inc., a provider of security equipment and systems, from March 2012 to February 2013. Mr. Sheridan served as Executive Vice President of Research and Development and Operations for Volcano Corporation (NASDAQ: VOLC), a medical technology company, from November 2004 to March 2010. From May 2002 to May 2004, Mr. Sheridan served as Executive Vice President of Operations at CardioNet, Inc., a medical technology company. From March 1998 to May 2002, he served as Vice President of Operations at Digirad Corporation, a medical imaging company. Mr. Sheridan holds a B.S. in Chemistry from the University of West Florida and an M.B.A. from Boston University.